KCG Holdings Inc. acquired a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000.

Galmed Pharmaceuticals Ltd. (GLMD) traded up 1.11% during trading on Friday, reaching $8.18. 19,028 shares of the company’s stock traded hands. The company’s market cap is $99.95 million. The company has a 50 day moving average price of $6.96 and a 200-day moving average price of $5.39. Galmed Pharmaceuticals Ltd. has a 12-month low of $2.78 and a 12-month high of $8.60.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.11. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.29 million. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. On average, equities research analysts forecast that Galmed Pharmaceuticals Ltd. will post ($0.94) EPS for the current fiscal year.

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/kcg-holdings-inc-invests-100000-in-galmed-pharmaceuticals-ltd-nasdaqglmd/1479071.html.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a report on Wednesday, August 2nd. Maxim Group reaffirmed a “buy” rating and issued a $14.00 price target (up from $9.00) on shares of Galmed Pharmaceuticals in a report on Monday, July 31st. HC Wainwright lifted their price target on shares of Galmed Pharmaceuticals from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, ValuEngine raised shares of Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 17th.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Want to see what other hedge funds are holding GLMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD).

Institutional Ownership by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.